Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Benjamin Greiner

Internal Medicine Tulsa, OK Doctor of Osteopathy

NPI 1902428212 CMS profile 8227420

6600 S Yale Ave Ste 600, Tulsa, OK 74136

Open in the dashboard

General payments

$3,569

130 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Greiner of Tulsa, OK is reported in the CMS Open Payments database as having received $3,569 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,152 62
2024 General $1,220 62
2023 General $197 5
2022 General $1,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Greiner
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Benjamin Greiner were reported at $1,152. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Benjamin Greiner Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $1,000 $141 $42–$496 $149
2023 $197 $149 $45–$519 $160
2024 $1,220 $154 $47–$537 $164
2025 $1,152 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Regeneron Pharmaceuticals, Inc. $1,000 1 payment
  2. AstraZeneca Pharmaceuticals LP $441 18 payments
  3. Novo Nordisk Inc $352 19 payments
  4. GlaxoSmithKline, LLC. $255 17 payments
  5. Pfizer Inc. $234 12 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $202 5 payments
  7. Astellas Pharma US Inc $135 6 payments
  8. Lilly USA, LLC $133 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $119 7 payments
  10. Eisai Inc. $75 3 payments
  11. Other $623 35 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,569 129 payments
  2. Grant $1,000 1 payment
Products named General payments · program years 2022–2025
  1. FARXIGA $320 11 payments
  2. TRELEGY ELLIPTA $255 17 payments
  3. AIRSUPRA $178 8 payments
  4. PREVNAR 20 $155 8 payments
  5. ABRYSVO $155 8 payments
  6. COMIRNATY $155 8 payments
  7. Wegovy $138 9 payments
  8. Veozah $135 6 payments
  9. Kerendia $119 7 payments
  10. MOUNJARO $85 5 payments
  11. Other $1,202 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 165 drugs

Part D claims

9,634

Median for Internal Medicine: 777

Drug cost

$956,129

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 166 $140,907
Jardiance Empagliflozin Brand 107 $124,249
Ozempic Semaglutide Brand 121 $120,513
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 128 $87,806
Mounjaro Tirzepatide Brand 49 $63,237
Xarelto Rivaroxaban Brand 40 $37,488
Januvia Sitagliptin Phosphate Brand 24 $30,273
Entresto Sacubitril/Valsartan Brand 19 $23,646
Rybelsus Semaglutide Brand 23 $23,219
Tresiba Flextouch U-200 Insulin Degludec Brand 18 $20,911

The 10 drugs with the highest cost, of 165 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$92,114

Of which drugs: $7,699

Medicare patients

524

Average age 77

Services billed

2,296

292 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 37%
Chronic kidney disease 25%
Depression 25%
Diabetes 24%
Ischemic heart disease 24%
Atrial fibrillation 18%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,637
Vaccine for influenza for injection into muscle 90653 Office 34 34 $2,782

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $152
$152 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $133
$133 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $103
$103 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $94
$94 128 —
Wegovy
  • Novo Nordisk Inc $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record